申请人:Sankyo Company Limited
公开号:EP0987269A1
公开(公告)日:2000-03-22
The below-described compound has good oral adsorption and exhibits markedly excellent antagonistic action against both NK1 receptors and NK2 receptors.
Hydrochloride or fumarate of 1-2-[(2R)-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl}spiro[benzo(c)thiophene-1(3H),4'-piperidin]-(2S)-oxide.
下述化合物具有良好的口服吸附性,对 NK1 受体和 NK2 受体都有明显的出色拮抗作用。
1-2-[(2R)-(3,4-二氯苯基)-4-(3,4,5-三甲氧基苯甲酰基)吗啉-2-基]乙基}螺[苯并(c)噻吩-1(3H),4'-哌啶]-(2S)-氧化物的盐酸盐或富马酸盐。